Kidney
- Home
- Cancer Infomation
Etiology & Risk Factors
Renal Cell Carcinoma (RCC) accounts for approximately 90% of all kidney malignancies. The development of RCC is a complex interplay between environmental exposures and specific genetic alterations.
Environmental & Lifestyle Triggers:
- Tobacco Use
- Obesity
- Hypertension
- Occupational Exposures: Trichloroethylene and cadmium exposure.
Genetic Predispositions
- VHL Syndrome: Mutations in the VHL gene (3p25) are the most common cause of hereditary clear cell RCC.
- Hereditary Papillary RCC: Associated with mutations in the MET proto-oncogene.
- BAP1 & PBRM1 Mutations are markers for aggressive tumor behavior.
- Chronic Kidney Disease (CKD): Patients on long-term dialysis often develop acquired cystic kidney disease, which carries a higher risk of malignancy.
Clinical Manifestations (Symptoms)
Early-Stage:
Advanced-Stage:
- hematuria (blood in urine)
- flank pain
- palpable abdominal mass
- Systemic Symptoms: Weight loss, night sweats, and persistent pyrexia (fever).
Paraneoplastic Syndromes:
- Hypercalcemia: Due to parathyroid hormone-related protein (PTHrP).
- Erythrocytosis: Elevated red blood cell count due to excess Erythropoietin (EPO) production.
- Stauffer Syndrome: Reversible hepatic dysfunction in the absence of liver metastases.
Diagnostic Workup
The diagnostic pathway emphasizes “precision staging” to minimize invasive procedures where possible.
- Imaging (Gold Standard): Triple-phase Multidetector CT (MDCT) or MRI with contrast of Abdomen and Pelvis. These modalities evaluate tumor enhancement, vascular involvement, and the health of the contralateral kidney.
- Role of PET CT: FDG-PET was limited in RCC due to urinary tracer excretion. Not routinely used for early tumors. Highly effective for detecting bone and soft tissue metastases that may be subtle on CT. High SUV-max on FDG-PET correlates with aggressive histology and poorer prognosis
- Renal Mass Biopsy (RMB): controversial, not routinely indicated except in very rare cases of small renal mass (SRMs) and where radiology reports has diagnostic dilemma.
- Liquid Biopsy: Circulating tumor DNA (ctDNA) and methylated DNA markers are now utilized to monitor minimal residual disease (MRD) post-surgery and to detect early relapse.
Cancer Stage
The diagnostic pathway emphasizes “precision staging” to minimize invasive procedures where possible.
Stage 0
Stage 1
Stage 2
Stage 3
Stage 4
Treatment Overview
1. Surgery
- Partial Nephrectomy (Nephron-Sparing): The gold standard for early stage tumors. It preserves renal function and reduces the long-term risk of cardiovascular disease.
- Radical Nephrectomy: Reserved for tumors where the tumor is too central or large to leave functional tissue behind. Often performed robotically.
2. Radiotherapy
- SBRT (Stereotactic Body Radiation Therapy): RCC was historically considered "radioresistant," but high-dose, ablative SBRT is now highly effective for primary tumors in medically inoperable patients or for treating oligometastatic sites (e.g., brain or bone mets).
3. Systemic Therapy
Modern treatment for metastatic RCC (mRCC) is rarely chemotherapy-based, focusing instead on targeted and immune pathways.
- Immunotherapy (ICI): Dual Checkpoint Inhibition (e.g., Nivolumab + Ipilimumab) or ICI/TKI combinations (e.g., Pembrolizumab + Axitinib).
- Targeted Therapies (TKIs): VEGF-targeted inhibitors such as Cabozantinib, Pazopanib, Lenvatinib, and Sunitinib.
- HIF-2α Inhibitors: Belzutifan is now a standard of care for VHL-associated RCC and is increasingly used in later-line refractory clear cell RCC.
Emerging Therapies
The landscape of RCC has been transformed by two major advancements:
- Antibody-Drug Conjugates (ADCs): New ADCs targeting CD70 and AXL are providing a "guided missile" approach, delivering cytotoxic agents directly to kidney cancer cells while sparing healthy tissue.
- AI-Driven Radiomics: AI algorithms now analyze CT/MRI textures to predict the specific histological subtype (Clear Cell vs. Chromophobe) and Fuhrman grade with 95% accuracy, often reducing the need for invasive biopsies.
Medical Disclaimer
This information is intended for educational and professional informational purposes only.
It does not constitute medical advice, diagnosis, or treatment.
Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.
Never disregard professional medical advice or delay in seeking it because of something you have read here.